A Look At TG Therapeutics (TGTX) Valuation After Record Q1 Revenue And Higher 2026 Guidance

Simply Wall St.05-10

TG Therapeutics (TGTX) drew fresh attention after record-setting Q1 2026 revenue tied to BRIUMVI, a higher full year revenue outlook of about US$925 million, and progress on key Phase 3 clinical ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2634422354?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","is_english":true,"pubTime":"2026-05-10 18:32","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2634422354","market":"nz","top_or_hot":-1,"title":"A Look At TG Therapeutics (TGTX) Valuation After Record Q1 Revenue And Higher 2026 Guidance","media":"Simply Wall St.","content":"<div>\n<p>TG Therapeutics (TGTX) drew fresh attention after record-setting Q1 2026 revenue tied to BRIUMVI, a higher full year revenue outlook of about US$925 million, and progress on key Phase 3 clinical ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tgtx/tg-therapeutics/news/a-look-at-tg-therapeutics-tgtx-valuation-after-record-q1-rev\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>A Look At TG Therapeutics (TGTX) Valuation After Record Q1 Revenue And Higher 2026 Guidance</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nA Look At TG Therapeutics (TGTX) Valuation After Record Q1 Revenue And Higher 2026 Guidance\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-05-10 18:32 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tgtx/tg-therapeutics/news/a-look-at-tg-therapeutics-tgtx-valuation-after-record-q1-rev><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>TG Therapeutics (TGTX) drew fresh attention after record-setting Q1 2026 revenue tied to BRIUMVI, a higher full year revenue outlook of about US$925 million, and progress on key Phase 3 clinical ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tgtx/tg-therapeutics/news/a-look-at-tg-therapeutics-tgtx-valuation-after-record-q1-rev\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TGTX","symbol_name":"TG Therapeutics Inc.","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tgtx/tg-therapeutics/news/a-look-at-tg-therapeutics-tgtx-valuation-after-record-q1-rev","article_id":"2634422354","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tgtx/tg-therapeutics/news/a-look-at-tg-therapeutics-tgtx-valuation-after-record-q1-rev","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2634422354","pubTimestamp":1778409160,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"TG Therapeutics (TGTX) drew fresh attention after record-setting Q1 2026 revenue tied to BRIUMVI, a higher full year revenue outlook of about US$925 million, and progress on key Phase 3 clinical milestones.\nSee our latest analysis for TG Therapeutics.\nThe recent six day rally, with a 7 day share price return of 27.37% and a 90 day share price return of 49.08%, suggests momentum has strengthened around Q1 results, raised 2026 guidance and upcoming BRIUMVI Phase 3 readouts. The 1 year total...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"TGTX":"TG Therapeutics Inc.","TG":"特里迪加"},"translate_title":"在创纪录的第一季度收入和更高的2026年指引后，看看TG Therapeutics(TGTX)的估值","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TG":1.5,"TGTX":1.5},"content_text":"TG Therapeutics (TGTX) drew fresh attention after record-setting Q1 2026 revenue tied to BRIUMVI, a higher full year revenue outlook of about US$925 million, and progress on key Phase 3 clinical milestones. See our latest analysis for TG Therapeutics. The recent six day rally, with a 7 day share price return of 27.37% and a 90 day share price return of 49.08%, suggests momentum has strengthened around Q1 results, raised 2026 guidance and upcoming BRIUMVI Phase 3 readouts. The 1 year total shareholder return of 27.07% points to meaningful gains over a longer holding period. If you are looking beyond a single biotech story, this is a useful moment to scan other healthcare AI opportunities using the 35 healthcare AI stocks After a rapid move that added roughly US$1.4b in market value and left the stock around 12% below the average analyst price target, the key question is whether TGTX still trades at a discount or if the market is already pricing in future growth. AdvertisementMost Popular Narrative: 3.2% Undervalued The most followed narrative pegs TG Therapeutics' fair value at about $44.43 per share, only slightly above the recent $43.03 close, which keeps attention fixed on the underlying growth story and its assumptions.  The planned launch of subcutaneous (subcu) BRIUMVI is a significant upcoming catalyst, as it could unlock access to 35-40% of the anti-CD20 MS market segment currently dominated by self-administered therapies, greatly increasing BRIUMVI's addressable market and supporting long-term revenue growth.  Read the complete narrative. Curious what kind of revenue ramp, margin reset, and future P/E this narrative leans on. The confidence comes from specific, quantified targets, not vague optimism. Result: Fair Value of $44.43 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, this hinges on BRIUMVI staying on track. Any setback in MS competition, pricing, or the early stage pipeline could quickly weaken that underpriced narrative. Find out about the key risks to this TG Therapeutics narrative. Next Steps With mixed signals across growth, valuation and sentiment, this is the moment to look at the numbers yourself, move quickly and shape your own view using the 4 key rewards and 1 important warning sign Looking for more investment ideas? If TGTX has your attention, do not stop here. Use this momentum to line up your next set of opportunities before the crowd catches on.  Hunt for quality at a better price by scanning 51 high quality undervalued stocks that combine solid fundamentals with room for potential upside. Build a sturdier core for your portfolio by checking solid balance sheet and fundamentals stocks screener (44 results) that may better handle shocks and funding needs. Add some under-the-radar potential by reviewing the screener containing 23 high quality undiscovered gems that many investors may not be watching yet.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n        and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n        financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n        Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n        Simply Wall St has no position in any stocks mentioned.Valuation is complex, but we're here to simplify it.Discover if TG Therapeutics might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2634422354","isCrawlerRequest":true}